Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 18;12:704112. doi: 10.3389/fphar.2021.704112

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Guo, Liu, Cheng, Liu, Zheng, Liang and Xu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The effect of metformin on reducing body weight and alleviating hepatic steatosis remains in SIRT1 deficient mice. SIRT1 deficiency did not impair the beneficial effects of metformin in (A) body weight, (B) fasting blood glucose and (C) body fat mass (p < 0.05). (D) Energy intake remained unaffected in Sirt1 ^+/− mice (p > 0.05). Metformin improved (E) glucose tolerance and (F) insulin sensitivity in Sirt1 ^+/− mice. (G) Liver weight, (H) the liver weight to body weight ratio, (I) the H&E staining, and the Oil Red O staining with ×400 magnification also showed that metformin alleviated hepatic steatosis in Sirt1 ^+/− mice (p < 0.05). (J) SIRT1 protein expression was lower in liver of Sirt1 ^+/− mice. Data are shown as mean ± SEM. *p < 0.05 WT + HFD + Metformin or Sirt1 ^+/− + HFD vs. WT + HFD group; ^# p < 0.05, Sirt1 ^+/− + HFD + Metformin vs. Sirt11 ^+/− + HFD group.